MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells

Jing,Changwen; Li,Huizi; Du,Yuanyuan; Cao,Haixia; Liu,Siwen; Wang,Zhuo; Ma,Rong; Feng,Jifeng; Wu,Jianzhong

doi:10.3892/mmr.2018.9730

MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells

Authors:
- Changwen Jing
- Huizi Li
- Yuanyuan Du
- Haixia Cao
- Siwen Liu
- Zhuo Wang
- Rong Ma
- Jifeng Feng
- Jianzhong Wu
View Affiliations

Affiliations: Clinical Cancer Research Center, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China, The Fourth Clinical School of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Chemotherapy, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China
Published online on: December 7, 2018 https://doi.org/10.3892/mmr.2018.9730
Pages: 1092-1100
Copyright: © Jing et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitogen‑activated protein kinase kinase (MEK) small molecule inhibitors have been investigated in preclinical or clinical trials for the treatment of cancer. In the present study the genetic test results of 120 patients with colorectal cancer (CRC) were screened and the mutation rate of MEK1 was identified to be 1.67%. MEK inhibition by U0126 significantly decreased the growth of SW48 cells that harbored the MEK1 Q56P mutation, although it did not evidently affect the growth of NCI‑H508 cells with MEK1 wild‑type. In addition, U0126 increased the sensitivity of SW48 cells to 5‑fluorouracil (5‑FU) and oxaliplatin by producing more γH2AX foci and decreasing the expression of excision repair cross‑complementation group 1 and thymidylate synthase. The results suggested that MEK inhibitors in combination with oxaliplatin/5‑FU may offer an improved therapeutic effect in patients with MEK‑mutant CRC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clini. 66:7–30. 2016. View Article : Google Scholar
2	Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005. View Article : Google Scholar : PubMed/NCBI
3	Chiu SJ, Lee YJ, Hsu TS and Chen WS: Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells. Chem Biol Interact. 182:173–182. 2009. View Article : Google Scholar : PubMed/NCBI
4	Fremin C and Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 3:82010. View Article : Google Scholar : PubMed/NCBI
5	Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 273:18623–18632. 1998. View Article : Google Scholar : PubMed/NCBI
6	Stepanenko A, Andreieva S, Korets K, Mykytenko D, Huleyuk N, Vassetzky Y and Kavsan V: Step-wise and punctuated genome evolution drive phenotype changes of tumor cells. Mutat Res. 771:56–69. 2015. View Article : Google Scholar : PubMed/NCBI
7	Rusch VW, Rice TW, Crowley J, Blackstone EH, Rami-Porta R and Goldstraw P: The seventh edition of the American joint committee on cancer/international union against cancer staging manuals: The new era of data-driven revisions. J Thorac Cardiovasc Surg. 139:819–821. 2010. View Article : Google Scholar : PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Motoyama N and Naka K: DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev. 14:11–16. 2004. View Article : Google Scholar : PubMed/NCBI
10	Rogakou EP, Nieves-Neira W, Boon C, Pommier Y and Bonner WM: Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J BiolChem. 275:9390–9395. 2000.
11	Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB, Hoeijmakers JH and Kanaar R: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol. 24:5776–5787. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B and Fassnacht M: Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr-Relat Cancer. 16:907–918. 2009. View Article : Google Scholar : PubMed/NCBI
13	Lu M, Gao J, Wang XC and Shen L: Expressions of thymidylate synthase, thymidine phosphorylase, class III beta-tubulin, and excision repair cross-complementing group 1predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin. Chin J Cancer Res. 23:288–294. 2011. View Article : Google Scholar : PubMed/NCBI
14	Grady WM and Pritchard CC: Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol. 42:124–139. 2014. View Article : Google Scholar : PubMed/NCBI
15	Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
16	Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB and Ladanyi M: MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res. 21:1935–1943. 2015. View Article : Google Scholar : PubMed/NCBI
17	Sogabe S, Togashi Y, Kato H, Kogita A, Mizukami T, Sakamoto Y, Banno E, Terashima M, Hayashi H, de Velasco MA, et al: MEK inhibitor for gastric cancer with MEK1 gene mutations. Mol Cancer Ther. 13:3098–3106. 2014. View Article : Google Scholar : PubMed/NCBI
18	Jin W, Wu L, Liang K, Liu B, Lu Y and Fan Z: Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer. 89:185–191. 2003. View Article : Google Scholar : PubMed/NCBI
19	Yan Y, Li J, Han J, Hou N, Song Y and Dong L: Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. Anticancer Drugs. 26:540–546. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yu X, Li Z, Yu J, Chan MT and Wu WK: MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif. 48:503–510. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yamaguchi T, Kakefuda R, Tajima N, Sowa Y and Sakai T: Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 39:23–31. 2011.PubMed/NCBI
22	Watanabe M, Sowa Y, Yogosawa M and Sakai T: Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci. 104:687–693. 2013. View Article : Google Scholar : PubMed/NCBI
23	Pereira DM, Simões AE, Gomes SE, Castro RE, Carvalho T, Rodrigues CM and Borralho PM: MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget. 7:34322–34340. 2016. View Article : Google Scholar : PubMed/NCBI
24	Urick ME, Chung EJ, Shield WP III, Gerber N, White A, Sowers A, Thetford A, Camphausen K, Mitchell J and Citrin DE: Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clin Cancer Res. 17:5038–5047. 2011. View Article : Google Scholar : PubMed/NCBI
25	Gong J, Chen Y, Yang L, Pillai R, Shirasawa S and Fakih M: MEK162 enhances antitumor activity of 5-fluorouracil and trifluridine in KRAS-mutated human colorectal cancer cell lines. Anticancer Res. 37:2831–2838. 2017.PubMed/NCBI
26	Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998. View Article : Google Scholar : PubMed/NCBI
27	MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H and Olive PL: Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol. 79:351–358. 2003. View Article : Google Scholar : PubMed/NCBI
28	Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB and Li XQ: Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer. 69:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wakasa K, Kawabata R, Nakao S, Hattori H, Taguchi K, Uchida J, Yamanaka T, Maehara Y, Fukushima M and Oda S: Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells. PLoS One. 10:e01230762015. View Article : Google Scholar : PubMed/NCBI
30	Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, et al: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica Biophysica Acta. 1587:194–205. 2002. View Article : Google Scholar